Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 6/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KCNA3 | P22001 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL372547 | 0.84 | — | — | |
| Hydrochloric Acid SCHEMBL741807 | 0.82 | ALOX15 (0.42) | OPRM1OPRD1OPRK1SMN1; SMN2SLC22A1 | |
| SCHEMBL22441532 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL20447769 | 0.82 | ALOX15 (0.42) | OPRM1OPRD1OPRK1SMN1; SMN2SLC22A1 | |
| SCHEMBL12312663 | 0.81 | OPRM1 (0.36) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| Hydrochloric Acid SCHEMBL2391027 | 0.81 | OPRM1 (0.38) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL571438 | 0.80 | SMN1; SMN2 (0.44) | OPRM1OPRD1OPRK1SMN1; SMN2SLC22A1 | |
| SCHEMBL2507803 | 0.80 | ALOX15 (0.41) | OPRM1OPRD1OPRK1SMN1; SMN2SLC22A1 | |
| SCHEMBL4609435 | 0.79 | CYP3A4 (0.65) | OPRM1OPRD1OPRK1SMN1; SMN2LMNA | |
| SCHEMBL22962252 | 0.79 | OPRM1 (0.47) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399681-B2 | Substituted aminothiazolone indazoles as estrogen related receptor-alpha modulators | JANSSEN PHARMACEUTICA NV (BE) | 2013-03-19 | — | — | US | disclosed |
| US-20120302544-A1 | SUBSTITUTED AMINOTHIAZOLONE INDAZOLES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | BIGNAN GILLES (US) | 2012-11-29 | — | — | US | disclosed |
| US-8263781-B2 | Substituted aminothiazolone indazoles as estrogen related receptor-alpha modulators | JANSSEN PHARMACEUTICA NV (BE) | 2012-09-11 | — | — | US | disclosed |
| US-20110150864-A1 | SUBSTITUTED AMINOTHIAZOLONE INDAZOLES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302544-A1 | SUBSTITUTED AMINOTHIAZOLONE INDAZOLES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | ESR2, ESRRA, IGF1R | OPRM1 3161/4885OPRD1 2608/4885OPRK1 549/4885 |
| US-20110150864-A1 | SUBSTITUTED AMINOTHIAZOLONE INDAZOLES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | ESR2, ESRRA, IGF1R | OPRM1 3161/4885OPRD1 2608/4885OPRK1 549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.